ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 1811 • ACR Convergence 2024

    The Immune Map of Lupus Nephritis: A Spatially Resolved Kidney Proteomic Approach

    Chen-Yu Lee1, Matthew Caleb Marlin2, Xiaoping Yang1, Alessandra Ida Celia3, Vasileios Morkotinis4, Richard Furie5, Jill Buyon6, Chaim Putterman7, Jennifer Barnas8, Kenneth Kalunian9, Peter Izmirly10, Betty Diamond11, Anne Davidson12, Diane Kamen13, Jeff Hodgin14, the Accelerating Medicines Partnership RA/SLE15, Judith James2, Michelle Petri16, Joel Guthridge2, Avi Rosenberg1 and Andrea Fava1, 1Johns Hopkins UNiversity, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Sapienza University of Rome, Rome, Italy, 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Northwell Health, Manhasset, NY, 6NYU Grossman School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Safed, Israel, 8University of Rochester, Rochester, NY, 9University of California San Diego, La Jolla, CA, 10New York University Grossman School of Medicine, New York, NY, 11The Feinstein Institutes for Medical Research, Manhasset, NY, 12Feinstein Institutes for Medical Research, Manhasset, NY, 13Medical University of South Carolina, Charleston, SC, 14University of Michigan, Michigan, 15multiple, multiple, 16Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Treatment response rates in lupus nephritis (LN) remain suboptimal, highlighting the need for a better understanding of LN pathogenesis to enhance treatment strategies. Single-cell…
  • Abstract Number: 2238 • ACR Convergence 2024

    The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status

    George Karpouzas1, Piet Van RIel2, Elena Myasoedova3, Miguel Angel Gonzalez-Gay4, alfonso Corrales-Martínez5, Solbritt Rantapaa-Dahlqvist6, Petros Sfikakis7, Patrick Dessein8, Linda Tsang9, Carol Hitchon10, Hani El Gabalawy11, Virginia Pascual Ramos12, Irazu Contreras Yanez13, Iris Jazmín Colunga Pedraza14, Dionicio Galarza-Delgado15, jose Ramon Azpiri-Lopez16, Anne Grete Semb17, Durga P Misra18, Patrick Durez19, Brian Bridal Logstrup20, Ellen Margrethe Hauge21, George Kitas22 and Sarah Ormseth23, and ATACC-RA, 1Harbor-UCLA Medical Center, Torrance, CA, 2Radboud University Medical Center, Nijmegen, Netherlands, 3Mayo Clinic, Rochester, MN, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Umeå University, Umeå, Sweden, 7Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8University of Witwatersrand, Johannesburg, South Africa, 9University of Witwatersrand, Johanessburg, South Africa, 10University of Mannitoba, Winnipeg, Canada, 11University of Mannitoba, Winnipeg, MB, Canada, 12Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 13Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 14Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 15UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 16Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 17Diakonhjemmet Hospital, Oslo, Norway, 18Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 19UCLouvain, Louvain, Belgium, 20University of Aarhus, Aarhus, Denmark, 21Aarhus Universitetshospital, Aarhus, Denmark, 22The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 23The Lundquist Institute, Torrance, CA

    Background/Purpose: Disease activity associated with cardiovascular (CV) risk in rheumatoid arthritis (RA). Females with RA exhibit higher disease activity than males. Yet, males with RA…
  • Abstract Number: 2380 • ACR Convergence 2024

    Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort

    Angela Hu1, Lauren Erdman2, Dennisse Bonilla3, Qixuan Li3, Laura Patricia Whittall Garcia3, Dafna Gladman4 and Zahi Touma5, 1University of British Columbia, Vancouver, BC, Canada, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…
  • Abstract Number: 0052 • ACR Convergence 2024

    Single Cell RNA-sequencing Analysis Revealed Peripheral Blood and Synovial Alterations of Dendritic Cells in Rheumatoid Arthritis

    Yuichi Suwa1, Saeko Yamada1, Toshiyuki Ushijima2, Hideyuki Takahashi2, Tomohisa Okamura1, Yasuo Nagafuchi3 and Keishi Fujio4, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo-ku, Tokyo, Japan, 3Department of Functional Genomics and Immunological Diseases, Graduate Schoold of Medicine, the University of Tokyo, Tokyo, Japan, 4Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan

    Background/Purpose: Recent single cell analyses have unveiled novel dendritic cell (DC) subpopulations that could potentially be linked to rheumatoid arthritis (RA). This study aimed to…
  • Abstract Number: 0506 • ACR Convergence 2024

    24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report

    Takao Fujii1, Nami Okamoto2, Asami Abe3, Michiaki Takagi4, Nobunori Takahashi5, Atsuo Nakajima6, Ayako Nakajima7, Shingo Nakayamada8, Keiichiro Nishida9, Takeshi Kawaberi10, Naomi Sunaga10, Yuki Tsujita11, Sumi Chonan12, Masataka Kuwana13 and Yoshiya Tanaka14, 1Wakayama Medical University, Wakayama, Japan, 2Osaka Rosai Hospital, Sakai-city, Osaka, Japan, 3Niigata Rheumatic Center, Shibata, Japan, 4Yamagata University Faculty of Medicine, Yamagata, Japan, 5Nagoya University Graduate School of Medicine, Nagoya, Japan, 6Ueno Dialysis Clinic, Tokyo, Japan, 7Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, 8The First Department of Internal Medicine, University of Occupational and Environmental Health Japan,, Kitakyushu, Japan, 9Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 10Abbvie GK, Minato-Ku, Tokyo, Japan, 11AbbVie, Minato City Tokyo, Japan, 12Abbvie GK, Tokyo, Japan, 13Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 14Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

    Background/Purpose: Upadacitinib (UPA) was approved in 2020 in Japan for "the treatment of Rheumatoid arthritis (RA) with inadequate response to conventional therapy (including inhibition of…
  • Abstract Number: 0601 • ACR Convergence 2024

    Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib

    Peter C. Taylor1, Lihi Eder2, Yael Klionsky3, Fabian Proft4, Thomas Iyile5, Erin Mancl6, Priscila Magalhaes Reis Nakasato7, Xiaolan Ye8, Limei Zhou6 and Philip Mease9, 1University of Oxford, Oxford, United Kingdom, 2University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, 4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5AbbVie Inc., hyattsville, MD, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., Randolph, NJ, 8AbbVie Inc., Mettawa, IL, 9Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
  • Abstract Number: 0828 • ACR Convergence 2024

    Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Benjamin Terrier5, Bernhard Hellmich6, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 6Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…
  • Abstract Number: 1293 • ACR Convergence 2024

    Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares

    OKEOGHENE AKPOIGBE1, COMFORT ANIM-KORANTENG2, BETTINA ESCOLANO3, NI NI LWIN1, JOANNA PANGILINAN1 and Amanda Sammut4, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, Bronx, NY, 3New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 4New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

    Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…
  • Abstract Number: 1367 • ACR Convergence 2024

    Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY

    James Galloway1, Jérôme Avouac2, Gerd Burmester3, Roberto Caporali4, Thomas P.A. Debray5, Katrien Van Beneden6, Neil Betteridge7, Susana Romero Yuste8, Monia Zignani5, Patrick Verschueren9 and Karen Bevers10, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 3Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 5Alfasigma S.p.A., Bologna, Italy, 6Medical Affairs, Galapagos NV, Mechelen, Belgium, 7Neil Betteridge Associates, Lonodn, United Kingdom, 8Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, 10Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…
  • Abstract Number: 1519 • ACR Convergence 2024

    Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus

    Chunhui Chen1, Emily Wu2, Huong Do3 and Kyriakos Kirou3, 1New York Presbyterian Queens, Flushing, NY, 2Hospital for Special Surgery, Rochester, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Lymphopenia is common in patients with systemic lupus erythematosus (SLE), occurring in 75-90% of cases over the disease course. It can result from SLE…
  • Abstract Number: 1875 • ACR Convergence 2024

    Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research

    Liya Stolyar1, Diane Mar2, Yuhan Liu3, Esther Velasquez4, orr Sharpe5, Michael Weisman6, Liron Caplan7 and suzanne Tamang8, 1Palo Alto VA Medical Center/Stanford, Stanford, CA, 2Palo Alto VA Medical Center/Stanford University Medical Center, Palo Alto, CA, 3Stanford Medicine Quantitative Sciences Unit, Palo Alto, CA, 4Stanford Center for Population Health Sciences, Palo Alto, CA, 5Department of Immunology and Rheumatology, Stanford University, Stanford, CA, 6Stanford University, Los Angeles, CA, 7Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, 8Stanford University, Atherton, CA

    Background/Purpose: Acute exposure to air pollution has been associated with flares of psoriasis and chronic inflammatory arthritides in prior studies.  However, the impact of air pollution,…
  • Abstract Number: 2241 • ACR Convergence 2024

    Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Bindee Kuriya3, Sibel Aydin4, Ed Keystone5, Janet Pope6 and Claire Bombardier7, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto - Toronto, Toronto, ON, Canada, 4Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 6University of Western Ontario, London, ON, Canada, 7University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
  • Abstract Number: 2390 • ACR Convergence 2024

    Anti-Sm Antibody Titers Vary During SLE Disease Course

    Faye Megaris1, Emily Wu2 and Kyriakos Kirou3, 1CUNY School of Medicine, Astoria, NY, 2Hospital for Special Surgery, Rochester, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by positive antibodies to dsDNA and/or Sm which have high specificity for the disease. While anti-dsDNA titers are…
  • Abstract Number: 0103 • ACR Convergence 2024

    CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

    chun Li, Peking University People's Hospital, Beijing, China

    Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
  • Abstract Number: 0510 • ACR Convergence 2024

    Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis

    Ahmad Alsaber1, Adeeba Alherz2, Huda Khraiss3, Ghaydaa Aldabie4, balqees alawadhi5, Jiazhu Pan6, Adel Alawadhi7, KHULOUD MOHAMMED8, Hoda Tarakmeh9, Aqeel Muhanna10, Yaser Ali11 and mohammad Khudadah12, and Kuwait Registry for Rheumatic Diseases (KRRD), 1American University of Kuwait, Kuwait, Kuwait, 2Al-Amiri Hospital, Kuwait, Kuwait, 3Monash University, Melbourne, Queensland, Australia, 4ministry of health kuwait, kuwait, Kuwait, 5The Public Authority for Applied Education and Training (PAAET), Kuwait, Al Asimah, Kuwait, 6University of Strathclyde, Glasgow, Scotland, United Kingdom, 7Kuwait University, Kuwait, Kuwait, 8Farwaniya Hospital, Kuwait, Kuwait, 9MOH Kuwait, Kuwait, Kuwait, 10Ministry of Health, Kuwait, Al Farwaniyah, Kuwait, 11Mubarek Al Kabeer Hospital, Kuwait city, Kuwait, 12ministery of health, kuwait, Kuwait

    Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology